The trial went on for so long there was obviously something wrong. I also knew that with the huge variability with lupus the trial would have to be something special because it was so small, probably too small to allow for the huge variability in lupus cases. Frankly, forget cpn-10 at this stage is my message to investors. We have never heard of Numoda or whatever the real time reporting was to potential partners. I can only assume that this was simply useless.
The IP argument that Christian raises in relation to Nadolol is simply not valid. Anything can be challenged, but it does not mean it will be successful. Nadolol has a unique action on the lung, something the FDA accepted. The fact that other b-blockers do roughly the same thing and who cares, is not the way science works. Other academics have stated that nadolol has an action which is not similar to other b-blockers. Lots of complexity with different beta blockers in the way they influence the receptors in the lung. I don't have the source here but will post it if I find it.
Smoking cessation is regularly studied.... so I don't know. I assume that every psychiatric study must also be doubted on the basis that patients cannot be sifted in for psychological criteria.
There is also a very clear case for inhaled Nadolol. I won't go into it here. But it is possible to overdose on Nadolol orally, and it would be very nice to get the same effect in spray form without any potential side-effects. So what if its expensive to get to market, its a huge end market.
Well, Dr Glass came out of retirement to waste his time and millions of dollars of his money and his friends' money - I just don't buy that. There is just a certain bitterness to this guys blog which makes me wonder why he writes.
IVX Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)